稳定期系统性红斑狼疮患者糖皮质激素撤药后复发风险的评估与预测(PRESS):中国开放标签、多中心、非劣效性随机对照研究
PRESS试验为多中心、33周、开放标签、三臂、非劣效性随机对照研究,纳入持续临床 inactive 且维持低剂量糖皮质激素(GC)联合羟氯喹(HCQ)治疗的SLE患者,随机分为停药组、HCQ组和双维持组。33周时三组复发率分别为26.1%、11.2%和4.7%;停药组与双维持组比较未达到非劣效(复发率差21.4%,95%CI 12.3%至30.5%,P非劣效=0.238),HCQ组达到非劣效(复发率差6.5%,95%CI -0.5%至13.5%,P非劣效=0.034),且HCQ组复发少于停药组(p=0.006)。作者认为GC撤药在持续临床 inactive 的SLE患者中可能可行,HCQ维持对预防GC撤药后复发可发挥保护作用。
要点
- 33周复发率:停药组26.1%、HCQ组11.2%、双维持组4.7%。
- 停药组 vs 双维持组复发率差21.4%(95%CI 12.3%至30.5%),未达非劣效(P非劣效=0.238)。
- HCQ组 vs 双维持组复发率差6.5%(95%CI -0.5%至13.5%),达到非劣效(P非劣效=0.034)。
核心结论
- 作者认为,在持续临床 inactive 的SLE患者中,GC撤药可能可行。
- 作者认为,HCQ维持对预防GC撤药后疾病复发可发挥保护作用。
研究设计与样本
- PRESS试验为多中心、33周、开放标签、三臂、非劣效性设计的随机对照试验。
- 筛查持续临床 inactive 且维持低剂量GC联合HCQ治疗的SLE患者,合格者随机分为停药组(GC和HCQ均撤)、HCQ组(停GC但维持HCQ)和双维持组(GC和HCQ均继续)。
- 2016年11月3日至2021年8月13日期间,333例随机化后符合方案的患者纳入分析。
- 主要终点为33周时按SELENA-SLEDAI flare index定义的复发患者比例,进行两项平行非劣效性分析(停药组 vs 双维持组、HCQ组 vs 双维持组)。
主要发现
- 三组复发率分别为26.1%、11.2%和4.7%。
- 停药组与双维持组比较未达到非劣效(复发率差21.4%;95%CI 12.3%至30.5%;P非劣效=0.238)。
- HCQ组与双维持组比较达到非劣效(复发率差6.5%;95%CI -0.5%至13.5%;P非劣效=0.034)。
- HCQ组复发少于停药组(p=0.006)。
- 三组不良事件相似。
关键数值与推荐
- 复发定义采用SELENA-SLEDAI flare index。
- 非劣效性分析:停药组 vs 双维持组复发率差21.4%(95%CI 12.3%至30.5%),P非劣效=0.238,未达非劣效。
- 非劣效性分析:HCQ组 vs 双维持组复发率差6.5%(95%CI -0.5%至13.5%),P非劣效=0.034,达到非劣效。
临床怎么用
- 作者认为GC撤药在持续临床 inactive 的SLE患者中可能可行。
- 作者认为HCQ维持对预防GC撤药后复发可发挥保护作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To explore the relapse rate after glucocorticoid (GC) withdrawal with or without hydroxychloroquine (HCQ) maintenance in sustained clinically inactive systemic lupus erythematosus (SLE). METHODS: The PRESS trial is a multicentre, 33-week, open-label, three-arm, non-inferiority designed, randomised controlled trial. SLE patients with sustained clinically inactive disease who maintained on low-dose GC plus HCQ therapy were screened and qualified patients were randomly assigned to three groups: drug-free group (both GC and HCQ withdrew); HCQ group (discontinued GC but maintained HCQ); dual maintenance group (both GC and HCQ continued). The primary endpoint was to compare the proportion of patients experiencing a relapse as defined by the Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index flare index by 33 weeks. Two parallel non-inferiority analyses were performed (drug-free group vs dual maintenance group and HCQ group vs dual maintenance group). RESULTS: From 3 November 2016 to 13 August 2021, 333 participants complied with the protocol after randomisation were analysed. The relapse rates in the three groups were 26.1%, 11.2% and 4.7%, respectively. Compared with dual maintenance group, drug-free group failed to achieve non-inferiority significance (relapse rate difference 21.4%; 95% CI 12.3% to 30.5%; Pnon-inferiority=0.238), whereas HCQ group achieved non-inferiority (relapse rate difference 6.5%; 95% CI -0.5% to 13.5%; Pnon-inferiority=0.034). HCQ group also exhibited fewer relapses than drug-free group (p=0.006). Adverse events were similar among all three groups. CONCLUSIONS: GC withdrawal may be feasible in sustained clinically inactive SLE patients. HCQ maintenance can exert a protective role in preventing disease relapse after GC withdrawal. Trial registration number NCT02842814.
引用
- Fei Y, Zhao L, Wu L, et al. Evaluation and prediction of relapse risk in stable systemic lupus erythematosus patients after glucocorticoid withdrawal (PRESS): an open-label, multicentre, non-inferiority, randomised controlled study in China. Ann Rheum Dis. 2025. PMID: 39919900. doi:10.1136/ard-2024-225826
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。